Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson & Johnson, has received US Food and Drug Administration (FDA) approval for Tracleer (bosentan) to be used in paediatric patients with idiopathic or congenital pulmonary arterial hypertension (PAH).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The FDA has granted approval for a new 32mg tablet for oral suspension for Tracleer to treat PAH patients aged three and older.

PAH is a chronic and progressive disease that results in abnormally high blood pressure in the arteries between the heart and lungs of an affected person.

The life-threatening disorder does not allow the blood to flow normally through the lungs and forces the patient’s heart to work harder.

See Also:

Tracleer is an orally active endothelin receptor antagonist (ERA) that can be used to treat PAH patients by blocking the effects of the extra endothelin produced by their bodies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The therapy has the potential to improve pulmonary vascular resistance (PVR), which is expected to improve the patient’s exercising ability.

"Actelion has focused on the needs of the PAH community since Tracleer, our first treatment for PAH, was approved in 2001."

Actelion Pharmaceuticals US Medical senior vice-president Dr Gary Palmer said: “Actelion has focused on the needs of the PAH community since Tracleer, our first treatment for PAH, was approved in 2001.

“We’re pleased our portfolio of treatments continues to grow and paediatric PAH patients will now have an FDA-approved treatment option available.”

The Actelion medicine is currently the first treatment approved by the FDA for paediatric PAH patients in the US.

The company expects to make the 32mg oral treatment available by the fourth quarter of this year.

Image: Micrograph showing arteries in pulmonary hypertensive with marked thickening of the walls. Photo: courtesy of Yale Rosen from USA.